Biotech Acquisition Company Unit
BIOTU
BIOTU was delisted on the 2nd of February, 2023.
5 hedge funds and large institutions have $443K invested in Biotech Acquisition Company Unit in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 7 closing their positions.
50% less funds holding
Funds holding: 10 → 5 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
85% less capital invested
Capital invested by funds: $2.96M → $443K (-$2.52M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.02K |
| 2 |
CS
Clear Street
New York
|
+$69 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$889K |
| 2 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
-$494K |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$413K |
| 4 |
Walleye Capital
New York
|
-$369K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$218K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Millennium Management
New York
| $392K | -$49.5K | -5,000 | -11% |
|
2
Morgan Stanley
New York
| $48K | -$35.6K | -3,600 | -43% |
|
3
UBS Group
Zurich,
Switzerland
| $2K | -$4.6K | -465 | -69% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $1K | +$1.02K | +103 | New |
|
|
HF
5
HRT Financial
New York
| – | -$889K | -89,754 | Closed |
|
|
WCMNY
6
Westchester Capital Management (New York)
Valhalla,
New York
| – | -$494K | -50,000 | Closed |
|
|
7
Janus Henderson Group
London,
United Kingdom
| – | -$413K | -41,715 | Closed |
|
|
8
Walleye Capital
New York
| – | -$369K | -37,192 | Closed |
|
|
LCM
9
Landscape Capital Management
Englewood,
New Jersey
| – | -$218K | -22,034 | Closed |
|
|
SIA
10
SkyView Investment Advisors
Shrewsbury,
New Jersey
| – | -$31K | -3,183 | Closed |
|
|
WAM
11
Wolverine Asset Management
Chicago,
Illinois
| – | -$10K | -1,028 | Closed |
|
|
CS
12
Clear Street
New York
| – | +$69 | +7 | New |
|
BIOTU Hedge Fund Activity: Q2 2022 in Review
5 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q2 2022, worth a combined $443K — down 85% from $2.96M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BIOTU and 2 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $1.02K. The largest seller was HRT Financial, exiting entirely with an estimated $889K sold.
- 5 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q2 2022, down from 10 in Q1 2022.
- Funds reported $443K of Biotech Acquisition Company Unit stock for Q2 2022, down 85% quarter-over-quarter.
- 2 funds opened new Biotech Acquisition Company Unit positions in Q2 2022 and 7 closed out, a net change of -5 holders.
- The largest Biotech Acquisition Company Unit buyer in Q2 2022 was Tower Research Capital (TRC), an estimated $1.02K added.
- The largest Biotech Acquisition Company Unit seller in Q2 2022 was HRT Financial, an estimated $889K sold.
Based on aggregated 13F filings for Q2 2022.